多西他赛配合雷替曲塞治疗对胃癌晚期患者DKK-1、TFF3的影响

Effect of Docetaxel Combined with Raltitrexed on DKK-1 and TFF3 in Patients with Advanced Gastric Cancer

目的研究多西他赛配合雷替曲塞治疗对胃癌晚期患者分泌性蛋白Dickkopf(DKK-1)和三叶因子家族蛋白3(Trefoil Factor 3,TFF3)的影响。方法将于上海交通大学附属仁济医院进行治疗的84例肺癌晚期患者,按照随机数字表法分为对照组和试验组,每组各42例。对照组患者采用多西他赛化疗,试验组患者采用多西他赛配合雷替曲塞化疗。治疗后观察两组患者治疗效果,检测其Dickkopf(DKK-1)蛋白、三叶因子-3(Trefoil Factor 3,TFF3)水平以及临床受益反应(clinical benefit response,CBR)情况。结果治疗结果显示:试验组和对照组临床有效率分别为66.67%、28.57%,试验组疗效更佳,差异有统计学意义(P<0.01);治疗后,两组患者的DKK-1和TFF3两项指标水平显著下降,差异有统计学意义(P<0.01);其中,试验组指标明显低于对照组(P<0.05);治疗后,两组患者体质量增加程度和疼痛程度明显降低;两组患者体力恢复例数及不良反应例数比较,差异均无统计学意义(P>0.01)。结论采用多西他赛配合雷替曲塞化疗方案治疗胃癌晚期患者,患者病情恢复明显,血清DKK-1、TFF3水平显著下降,预后得到改善,值得在临床推广和应用。

Objective To study the effect of docetaxel combined with raltitrexed on Dickkopf （DKK-1） and Trefoil Factor 3 （TFF3） in patients with advanced gastric cancer. Methods A total of 84 patients with advanced gastric cancer treated in Renji Hospital of Shanghai Jiao Tong University were divided into the control group and the experiment group by the random number table method, and each group included 42 cases. The control group was given the chemotherapy with docetaxel, while the experiment group was given the chemotherapy with both docetaxel and raltitrexed. The therapeutic effects were observed and the levels of DKK-1 and TFF3 and the clinical benefit response （CBR） were determined. Results The clinical effective rate of the experiment group （66.67%） was significantly better than that of the control group （28.57%） （ P 〈0.01）. The levels of DKK-1 and TFF3 were significantly decreased after treatment in the two groups （ P 〈0.01）, and those were significantly lower in the experiment group than in the control group （ P 〈0.05）. The degrees of weight gain and pain in the two groups decreased obviously after treatment, but there was no statistical differences in the number of cases with antisecosis or adverse effect between the two groups （ P 〉0.01）. Conclusion The chemotherapy with both docetaxel and raltitrexed can significantly promote the recovery of patients by reducing the levels of DKK-1 and TFF3 and improving the prognosis in treatment of advanced gastric cancer, so it is worth the clinical popularization and application.